Preprint Article Version 1 This version is not peer-reviewed

Real-World Clinical Outcomes of Neoadjuvant Platinum-Based Chemotherapy with Nivolumab in Non-Small Cell Lung Cancer

Walid Shalata
* ,
Sameh Daher
,
Natali Maimon Rabinovitch
,
Sivan Shami
,
Waleed Kian
,
Ilit Turgeman
,
Yulia Dudnik
,
Olga Kazareen
,
Yulia Robetski
,
Edmond Sabo
,
Dan Levy Faber
,
Ronen Galili
,
Ory Wiesel
,
Konstantin Baranovsky
,
Abed Agbarya
*
Version 1 : Received: 29 September 2024 / Approved: 30 September 2024 / Online: 30 September 2024 (09:51:51 CEST)

How to cite: Shalata, W.; Daher, S.; Maimon Rabinovitch, N.; Shami, S.; Kian, W.; Turgeman, I.; Dudnik, Y.; Kazareen, O.; Robetski, Y.; Sabo, E.; Faber, D. L.; Galili, R.; Wiesel, O.; Baranovsky, K.; Agbarya, A. Real-World Clinical Outcomes of Neoadjuvant Platinum-Based Chemotherapy with Nivolumab in Non-Small Cell Lung Cancer. Preprints 2024, 2024092388. https://doi.org/10.20944/preprints202409.2388.v1 Shalata, W.; Daher, S.; Maimon Rabinovitch, N.; Shami, S.; Kian, W.; Turgeman, I.; Dudnik, Y.; Kazareen, O.; Robetski, Y.; Sabo, E.; Faber, D. L.; Galili, R.; Wiesel, O.; Baranovsky, K.; Agbarya, A. Real-World Clinical Outcomes of Neoadjuvant Platinum-Based Chemotherapy with Nivolumab in Non-Small Cell Lung Cancer. Preprints 2024, 2024092388. https://doi.org/10.20944/preprints202409.2388.v1

Abstract

This study aims to evaluate the outcomes of neoadjuvant chemotherapy with immunotherapy in patients with non-small cell lung cancer (NSCLC) within a real-world context. We analyzed medical records from January 2022 to August 2023, focusing on individuals aged 18 and older diagnosed with resectable NSCLC who received neoadjuvant chemoimmunotherapy prior to surgical intervention. The cohort comprised 56 patients, predominantly smokers (95%) and male (74%), with 80% presenting at stage III. Of the participants, 44 underwent surgery, with 95% receiving lobar resection. Clinical assessments via PET-CT imaging revealed an 86% rate of response or disease stabilization, while pathological evaluations showed complete and major pathological responses in 61% of cases. This real-world data supports the safety and efficacy of incorporating immune checkpoint inhibitors in the neoadjuvant treatment of NSCLC, followed by surgical resection.

Keywords

Neoadjuvant; Chemotherapy; Immunotherapy; Non-Small Cell Lung Cancer; Resection surgery; Real-world clinical outcomes

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.